Study of Biomarkers to Diagnose and Predict Lung Transplant Problems Including Risk of Rejection and Graft Failure

What this Trial Is About

Lung transplantation often has poorer long-term outcomes compared to other solid organ transplants, with an average survival of six years after the procedure. A major challenge is allograft rejection, which is the leading cause of illness and death in these patients beyond the first year. Researchers are studying the underlying biological mechanisms of transplant dysfunction using blood and tissue samples linked to clinical data to improve early and accurate diagnosis of these complications. This study involves collecting biological samples such as blood, biopsies, and hair from patients with lung disease who require or have undergone lung transplantation. There is no specific treatment or intervention given as part of the study. The focus is on evaluating non-invasive blood markers and gene expression profiles to better understand the risk of rejection and graft loss within the first year after transplant. Participants will be monitored over a period of up to 15 years, during which researchers will assess various biomarkers and gene sets related to transplant dysfunction and response to immunosuppressive treatments. The study also examines patient well-being and the costs associated with different diagnostic strategies. Throughout the study, participants will provide samples and clinical information to help stratify rejection risks and improve transplant outcomes.

Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation